Format

Send to

Choose Destination
See comment in PubMed Commons below
Liver Cancer. 2012 Nov;1(3-4):201-15. doi: 10.1159/000343835.

Combination of local transcatheter arterial chemoembolization and systemic anti-angiogenic therapy for unresectable hepatocellular carcinoma.

Author information

1
Division of Vascular and Interventional Radiology, Johns Hopkins University School of Medicine, Interventional Radiology Center, Baltimore, Maryland, USA.

Abstract

The pathophysiologic complexity of hepatocellular carcinoma (HCC) and underlying hepatic cirrhosis, make optimal treatment choice a clinical challenge. The radical change in the treatment algorithm of patients with advanced unresectable HCC over the past 7 years, with the introduction of anti-angiogenic agents in patients with only preserved liver function reflect this challenge. Even though data from studies on the combination of transcatheter arterial chemoembolization and anti-angiogenic agents demonstrate a survival advantage in selected patients, this combination is not straightforward. In this review, we'll examine current data of administering anti-angiogenic therapy in combination with transcatheter arterial chemoembolization and critically evaluate the progress and gaps in current knowledge.

KEYWORDS:

Angiogenesis; Clinical trials; Hepatocellular carcinoma; Transcatheter arterial chemoembolization

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Support Center